Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial

Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn, +23

PLoS Medicine

Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial

Raphael J. Landovitz, Sue Li, Joseph J. Eron, +19

The Lancet HIV

Treatment And PreventionPharmacologyAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy +6

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077

Elizabeth E. Tolley, Sahar Z. Zangeneh, Gordon Chau, +14

AIDS and Behavior

Hiv-uninfected IndividualsPharmacotherapyAntiviral DrugPreventive MedicineDaily Oral Prep +18

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, +39

The Lancet Infectious Diseases

VaccinationVaccine SafetyVaccine DevelopmentImmunologyVaccine Testing +5

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

Susan H. Eshleman, Jessica M. Fogel, Estelle Piwowar‐Manning, +30

The Journal of Infectious Diseases

Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus–uninfected Individuals in HPTN 077

Raphael J. Landovitz, Sahar Z. Zangeneh, Gordon Chau, +15

Clinical Infectious Diseases

Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial

Raburn M. Mallory, Neil Formica, Susan Pfeiffer, +16

ImmunologyImmunodominanceCovid-19Vaccine TargetVaccine Surveillance +16

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373

Katia Alves, Joyce S. Plested, Shirley Galbiati, +13

Vaccine

Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077

Cheríe Blair, Sue Li, Gordon Chau, +10

JAIDS Journal of Acquired Immune Deficiency Syndromes

The Longitudinal Effects of Non-injection Substance Use on Sustained HIV Viral Load Undetectability Among MSM and Heterosexual Men in Brazil and Thailand: The Role of ART Adherence and Depressive Symptoms (HPTN 063)

Kiyomi Tsuyuki, Steven Shoptaw, Yusuf Ransome, +8

AIDS and Behavior

Substance AbuseSexual HealthSubstance UsePsychiatryTreatment And Prevention +11